Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. FDX
4. CBRS
5. HTZ
6. USO
7. SPY
8. KBH
9. LAES
10. HON

Go back to Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma
DELCATH SYSTEMS (NASDAQ: DCTH) Delayed: 12.24 --0 (-0%)
Previous Close $12.24    52 Week High $4.72 
Open $12.24    52 Week Low $0.22 
Day High $12.24    P/E N/A 
Day Low $12.24    EPS $-102.40 
Volume 10